Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Liminal BioSciences Inc. LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed... see more

Recent & Breaking News (NDAQ:LMNL)

Liminal Biosciences Reports Fourth Quarter and 2019 Year End Results

Canada NewsWire March 20, 2020

Liminal BioSciences to report its fourth quarter and year-end 2019 financial results and hold conference call/webcast

Canada NewsWire March 20, 2020

Liminal BioSciences Announces Scientific Presentations at Upcoming Keystone Symposia

Canada NewsWire February 12, 2020

Liminal BioSciences announces upcoming investor presentation at BIO CEO & Investor Conference

Canada NewsWire February 6, 2020

Liminal BioSciences Outlines Corporate Priorities for 2020

PR Newswire January 13, 2020

Liminal BioSciences Comments on Unusual Market Activity

Canada NewsWire December 23, 2019

AMF Concludes its Review of the Refinancing Transactions Completed by Liminal BioSciences in April 2019

PR Newswire November 28, 2019

Liminal BioSciences to Present at Piper Jaffray Healthcare Conference

PR Newswire November 27, 2019

Liminal BioSciences announces closing of divestiture of bioseparations division to KKR

Canada NewsWire November 25, 2019

Liminal Presents New Preclinical Data on PBI-4050 and its Effect on Angio-Proliferative Pulmonary Arterial Hypertension

Canada NewsWire November 18, 2019

Liminal BioSciences to Present at the Jefferies 2019 London Healthcare Conference

Canada NewsWire November 18, 2019

Liminal Biosciences announces effectiveness of Registration Statement on Form F-10 and filing of Prospectus Supplement

Canada NewsWire November 18, 2019

Liminal BioSciences to Present at Stifel Healthcare Conference

Canada NewsWire November 15, 2019

Liminal BioSciences to Commence Trading Common Shares on NASDAQ

Canada NewsWire November 15, 2019

/C O R R E C T I O N from Source -- Liminal BioSciences Inc./

Canada NewsWire November 14, 2019

Liminal Biosciences Announces Key Appointment to its Leadership Team

Canada NewsWire November 13, 2019

Liminal BioSciences Presents New Preclinical Data on PBI-4050 and NASH Candidate PBI-4547

Canada NewsWire November 12, 2019

Liminal BioSciences to Report Q3 2019 Results and Hold Conference Call

Canada NewsWire November 11, 2019

Liminal BioSciences Reports its 2019 Third Quarter Financial Results and Business Highlights

Canada NewsWire November 11, 2019

Liminal Biosciences Presents New Preclinical Data at ASN Kidney Week 2019

Canada NewsWire November 11, 2019